Identification and Experimental Validation of a Sialylation-related Long Noncoding RNA Signature for Prognosis of Bladder Cancer

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2024 Oct 10

PMID 39390546

Authors

Yi Qiao

Xintao Tian

Shengxian Li

Haitao Niu

Affiliations

Soon will be listed here.

Abstract

Background: The dysregulation of sialylation plays a pivotal role in cancer progression and metastasis, impacting various aspects of tumor behavior. This study aimed to investigate the prognostic significance of long non-coding RNAs (lncRNAs) in relation to sialylation. Additionally, we aimed to develop a signature of sialylation-related lncRNAs in the context of bladder cancer.

Methods: This study used transcriptomic data and clinical information from the TCGA (the Cancer Genome Atlas) database to screen for sialylation-related lncRNAs and constructed a prognostic model. The relationships between these lncRNAs and biological pathways, immune cell infiltration, drug sensitivity, etc., were analyzed, and the expression of some lncRNAs was validated at the cellular level.

Results: This study identified 6 prognostic lncRNAs related to sialylation and constructed a risk score model with high predictive accuracy and reliability. The survival period of patients in the high-risk group was significantly lower than that of the low-risk group, and it was related to various biological pathways and immune functions. In addition, this study found differences in the sensitivity of patients in different risk groups to chemotherapy drugs, providing a reference for personalized treatment.

Conclusion: In this study, we examined the relationship between sialylation-related lncRNA and the prognosis of bladder cancer, providing new molecular markers and potential targets for diagnosis and treatment. Our research revealed correlations between sialylation-related lncRNA characteristics and clinicopathological features, potential mechanisms, somatic mutations, immune microenvironment, chemotherapy response, and predicted drug sensitivity in bladder cancer. Additionally, in vitro cellular studies were conducted to validate these findings and lay the groundwork for future clinical applications.

References

Li F, Ding J . Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell. 2018; 10(8):550-565. PMC: 6626595. DOI: 10.1007/s13238-018-0597-5. View

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

Bull C, Heise T, Adema G, Boltje T . Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis. Trends Biochem Sci. 2016; 41(6):519-531. DOI: 10.1016/j.tibs.2016.03.007. View

Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

Ikehara Y, Ikehara S, Paulson J . Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem. 2004; 279(41):43117-25. DOI: 10.1074/jbc.M403538200. View

Rokavec M, Oner M, Li H, Jackstadt R, Jiang L, Lodygin D . IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014; 124(4):1853-67. PMC: 3973098. DOI: 10.1172/JCI73531. View

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

Varki A . Sialic acids in human health and disease. Trends Mol Med. 2008; 14(8):351-60. PMC: 2553044. DOI: 10.1016/j.molmed.2008.06.002. View

10.

Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S . Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021; 6(1):153. PMC: 8062524. DOI: 10.1038/s41392-021-00544-0. View

11.

Jian Y, Chen Q, Al-Danakh A, Xu Z, Xu C, Sun X . Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis. Int Immunopharmacol. 2024; 138:112569. DOI: 10.1016/j.intimp.2024.112569. View

12.

Nieto M, Huang R, Jackson R, Thiery J . EMT: 2016. Cell. 2016; 166(1):21-45. DOI: 10.1016/j.cell.2016.06.028. View

13.

Sathianathen N, Regmi S, Gupta S, Konety B . Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer. Urol Clin North Am. 2019; 47(1):103-110. DOI: 10.1016/j.ucl.2019.09.012. View

14.

Varki A . Biological roles of glycans. Glycobiology. 2016; 27(1):3-49. PMC: 5884436. DOI: 10.1093/glycob/cww086. View

15.

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

16.

Macauley M, Crocker P, Paulson J . Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014; 14(10):653-66. PMC: 4191907. DOI: 10.1038/nri3737. View

17.

Schauer R . Achievements and challenges of sialic acid research. Glycoconj J. 2001; 17(7-9):485-99. PMC: 7087979. DOI: 10.1023/a:1011062223612. View

18.

Mounir M, Lucchetta M, C Silva T, Olsen C, Bontempi G, Chen X . New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol. 2019; 15(3):e1006701. PMC: 6420023. DOI: 10.1371/journal.pcbi.1006701. View

19.

Videira P, Correia M, Malagolini N, Crespo H, Ligeiro D, Calais F . ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 2009; 9:357. PMC: 2763879. DOI: 10.1186/1471-2407-9-357. View

20.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View